- Home
- ABT
as 06-06-2025 4:00pm EST
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
| Founded: | 1888 | Country: | United States |
| Employees: | N/A | City: | ABBOTT PARK |
| Market Cap: | 221.0B | IPO Year: | N/A |
| Target Price: | $140.44 | AVG Volume (30 days): | 6.1M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.70 | EPS Growth: | 139.92 |
| 52 Week Low/High: | $99.71 - $141.23 | Next Earning Date: | 07-17-2025 |
| Revenue: | $42,344,000,000 | Revenue Growth: | 5.00% |
| Revenue Growth (this year): | 7.53% | Revenue Growth (next year): | 7.69% |
Stock Insider Trading Activity of Abbott Laboratories (ABT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Blount Sally E. | ABT | Director | Apr 30 '25 | Sell | $129.66 | 2,600 | $337,116.00 | 34,058 |
Latest Abbott Laboratories News
ABT Breaking Stock News: Dive into ABT Ticker-Specific Updates for Smart Investing
Yahoo Finance
3 days ago
Omada Health goes public at $23 per share, marking second major digital health IPO in 2025
Zacks
4 days ago
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
Zacks
4 days ago
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note
Zacks
5 days ago
Emerging Markets Power Boston Scientific: Will the Growth Trend Continue?
Zacks
5 days ago
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Bloomberg
6 days ago
Media Groups Probed by FTC Over Coordinating Boycott Claims
MT Newswires
7 days ago
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $153 From $147, Maintains Buy Rating
Simply Wall St.
8 days ago
There's Been No Shortage Of Growth Recently For Abbott Laboratories' (NYSE:ABT) Returns On Capital
Compare ABT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABT Abbott Laboratories - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.